Mammoth eyes CRISPR-based therapeutics with new funding
CRISPR company Mammoth looks beyond diagnostics with Decheng Capital-led $45M series B
With a $45 million series B round led by Decheng Capital, Mammoth Biosciences is capitalizing on its IP position around an alternative CRISPR enzyme and expanding its gene editing capabilities beyond diagnostics into a range of therapeutic applications.
Mayfield, NFX, Verily and Brook Byers also participated in the round, which brings the company’s total funding to over $70 million to date.